LATEST

• BUSINESS Moderna Japan Looks Beyond COVID for Next Growth Pillars
  June 9, 2026

• COMMENTARY 20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag
  June 9, 2026

• BUSINESS Oncolys Targets 300 Hospitals for Telomelysin Rollout
  June 9, 2026

• REGULATORY MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
  June 9, 2026

• REGULATORY Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
  June 9, 2026

• ORGANIZATION Society Envisions 1 Trillion Yen in Overseas Sales for Japan’s Off-Patent Drug Sector by 2040
  June 9, 2026

• REGULATORY Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
  June 8, 2026

• BUSINESS CSL Behring Japan President Yoshida to Step Down
  June 8, 2026

• BUSINESS Japan Approves Oncolys’ Telomelysin for Esophageal Cancer
  June 8, 2026

• BUSINESS Takeda Swings to Loss after Booking Amitiza Litigation Charge
  June 8, 2026

• BUSINESS GNI to Acquire Ayumi Pharma in 44.8 Billion Yen Deal
  June 8, 2026

• BUSINESS Shionogi Releases Japan’s First Therapy App for Pediatric ADHD
  June 8, 2026

• ORGANIZATION Employees of 9 Pharma Firms Team Up for LGBTQ+ Inclusion
  June 8, 2026

• REGULATORY Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
  June 8, 2026

• REGULATORY Japan Tightens Oversight of Mounjaro Resales: Health Minister
  June 8, 2026

• BUSINESS Kaken Files Head Lice Treatment in Japan
  June 8, 2026

• BUSINESS UCB Japan Seeks Pediatric Use, Dry Syrup Approval for Briviact
  June 8, 2026

• BUSINESS Nobelpharma’s Nobelzin Makes China Debut for Wilson Disease
  June 8, 2026

• BUSINESS Japan Ethical Drug Sales Rise 7.3% in April: Crecon
  June 8, 2026

• ACADEMIA Japan Cancer Center Lowers Recommended BMI Ceiling for Men to 25
  June 5, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• …
• Next ›
• 最終 »